Tax Reform Provides Environment For M&A Surge, EY Report Says
Executive Summary
2018 should see an increase in significant biopharma deal-making, possibly even a mega-merger, as US companies are able to repatriate offshore cash at lower tax rates.
You may also be interested in...
Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Celgene believes it's acquiring a $1bn drug, not a me-too JAK inhibitor in its purchase of Impact Biomedicines for $1.1bn up front. Investors appeared skeptical of fedratinib's potential, but the company said at the J.P. Morgan meeting that it will execute more deals to build out its pipeline.